StockSelector.com
  Research, Select, & Monitor Tuesday, September 26, 2017 12:30:14 PM ET  
Trade Ideas The Market Industries Stocks Portfolio

 
Ticker Lookup
Johnson & Johnson$131.39$.22.17%

  Quote | Ranking | Chart | Valuations | Sentiment | Industry | News | Earnings | Analysts | More...

Your Target?

 Johnson & Johnson Reports 2017 Second-Quarter Results:
   Tuesday, July 18, 2017 6:40:00 AM ET

Johnson & Johnson (JNJ ) today announced sales of $18.8 billion for the second quarter of 2017, an increase of 1.9% as compared to the second quarter of 2016. Operational sales results increased 2.9% and the negative impact of currency was 1.0%. Domestic sales increased 1.6%. International sales increased 2.3%, reflecting operational growth of 4.4% and a negative currency impact of 2.1%. Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales increased 0.5%, domestic sales decreased 1.0% and international sales increased 2.0%.*

https://mma.prnewswire.com/media/403394/Johnson_and_Johnson_Logo.jpg

Net earnings and diluted earnings per share for the second quarter of 2017 were $3.8 billion and $1.40, respectively. Second-quarter 2017 net earnings included after-tax intangible amortization expense of approximately $0.4 billion and a charge for after-tax special items of approximately $0.8 billion. Second-quarter 2016 net earnings included after-tax intangible amortization expense of approximately $0.2 billion and a charge for after-tax special items of approximately $0.7 billion. Excluding after-tax intangible amortization expense and special items, adjusted net earnings for the current quarter were $5.0 billion and adjusted diluted earnings per share were $1.83, representing increases of 3.1% and 5.2%, respectively, as compared to the same period in 2016.* On an operational basis, adjusted diluted earnings per share also increased 6.9%.* A reconciliation of non-GAAP financial measures is included as an accompanying schedule.

"Our second-quarter results reflect strong adjusted earnings growth and we are optimistic that the investments we are making will accelerate our sales growth in the second half of this year. Our pharmaceutical pipeline continued its strong momentum with the approval of TREMFYA(TM) as well as the submission and approval of several key line extensions," said Alex Gorsky, Chairman and Chief Executive Officer. "The Actelion acquisition establishes a new therapeutic area as well as another engine for growth and we are pleased to welcome the Actelion colleagues to the Johnson & Johnson Family of Companies. Together with all of our businesses, we will continue to transform the lives of patients around the world."

The Company increased its sales guidance for the full-year 2017 to $75.8 billion to $76.1 billion. Additionally, the Company increased its adjusted earnings guidance for full-year 2017 to $7.12 - $7.22 per share.*

Worldwide Consumer sales of $3.5 billion for the second quarter 2017 represented an increase of 1.7% versus the prior year, consisting of an operational increase of 2.3% and a negative impact from currency of 0.6%. Domestic sales increased 7.4%, international sales decreased 2.2%, which reflected an operational decrease of 1.1% and a negative currency impact of 1.1%. Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales decreased 0.8%, domestic sales increased 1.2% and international sales decreased 2.3%*.

Worldwide operational results, excluding the net impact of acquisitions and divestitures, were negatively impacted by baby care products, partially offset by domestic over-the-counter products, including upper respiratory products and international anti-smoking aids, and NEUTROGENA? beauty products.

Worldwide Pharmaceutical sales of $8.6 billion for the second quarter 2017 represented a decrease of 0.2% versus the prior year with an operational increase of 1.0% and a negative impact from currency of 1.2%. Domestic sales decreased 2.6%; international sales increased 3.3%, which reflected an operational increase of 6.1% and a negative currency impact of 2.8%. Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales increased 0.5%, domestic sales decreased 2.6% and international sales increased 5.1%.* Worldwide operational sales growth was negatively impacted by approximately 4 points due to a positive adjustment of U.S. rebate accruals in the second quarter of 2016, which did not repeat in the second quarter of 2017.

Worldwide operational results, excluding the net impact of acquisitions and divestitures, were driven by new products and the strength of core products. Strong growth in new products include DARZALEX? (daratumumab), for the treatment of patients with multiple myeloma and IMBRUVICA? (ibrutinib), an oral, once-daily therapy approved for use in treating certain B-cell malignancies, a type of blood or lymph node cancer. Additional contributors to operational sales growth included STELARA? (ustekinumab), a biologic for the treatment of a number of immune-mediated inflammatory diseases, and INVEGA? SUSTENNA?/XEPLION?/TRINZA? (paliperidone palmitate), long-acting, injectable atypical antipsychotics for the treatment of schizophrenia in adults.

During the quarter, the Company announced the completion of the acquisition of Actelion Ltd., a leading biopharmaceutical company, for a total purchase price of approximately $30 billion in cash.

Also in the quarter, the U.S. Food and Drug Administration (FDA) approved an additional indication for DARZALEX? (daratumumab) in combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior therapies. The European Commission (EC) granted approval for DARZALEX? (daratumumab) for use in combination with lenalidomide and dexamethasone, or bortezomib (VELCADE?) and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.

In addition, a supplemental New Drug Application was submitted to the FDA to update the prescribing information for XARELTO? (rivaroxaban) to add a 10mg dose to reduce patients’ risk of recurrent venous thromboembolism (VTE) after at least six months of standard anticoagulation therapy and regulatory submissions were made to both the European Medicines Agency and the FDA for a single-tablet, two-drug regimen of dolutegravir and rilpivirine for the maintenance treatment of HIV-1 infection.

In July, subsequent to the quarter, the FDA approved TREMFYA(TM) (guselkumab) for the treatment of adults living with moderate to severe plaque psoriasis.

Worldwide Medical Devices sales of $6.7 billion for the second quarter 2017 represented an increase of 4.9% versus the prior year consisting of an operational increase of 5.9% and a negative currency impact of 1.0%. Domestic sales increased 6.1%; international sales increased 3.9%, which reflected an operational increase of 5.8% and a negative currency impact of 1.9%. Sales included the impact of the first full quarter of the recently completed acquisition of Abbott Medical Optics which contributed 5.1%, to worldwide operational sales growth. Excluding the net impact of all acquisitions and divestitures, on an operational basis, worldwide sales increased 1.1%, domestic sales increased 0.8% and international sales increased 1.4%.*

Worldwide operational results, excluding the net impact of acquisitions and divestitures, were driven by electrophysiology products in the Cardiovascular business, ACUVUE? contact lenses in the Vision Care business, and Advanced Surgery products, partially offset by declines in the Diabetes Care business.

During the quarter, FDA clearance was received for the 30-minute STERRAD VELOCITY(TM) Biological Indicator System for low temperature H202 sterilization as well as approval for the SURGICEL? Powder Absorbable Hemostat for adjunctive hemostasis during surgery.

About Johnson & Johnson

Caring for the world, one person at a time, inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 132,500 employees at more than 250 Johnson & Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

* Operational sales growth excluding the net impact of acquisitions and divestitures, as well as adjusted net earnings, adjusted diluted earnings per share and operational adjusted diluted earnings per share excluding after-tax intangible amortization expense and special items, are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. Except for guidance measures, reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investor Relations section of the company’s website at www.investor.jnj.com. Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the company is unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses, acquisition-related expenses and purchase accounting fair value adjustments without unreasonable effort. These items are uncertain, depend on various factors, and could be material to Johnson & Johnson’s results computed in accordance with GAAP.

Johnson & Johnson will conduct a conference call with investors to discuss this news release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the Johnson & Johnson website at www.investor.jnj.com. A replay and podcast will be available approximately two hours after the live webcast by visiting www.investor.jnj.com.

Copies of the financial schedules accompanying this press release are available at www.investor.jnj.com/historical-sales.cfm. These schedules include supplementary sales data, a condensed consolidated statement of earnings, reconciliations of non-GAAP financial measures, and sales of key products/franchises. Additional information on Johnson & Johnson, including adjusted income before tax by segment, a pharmaceutical pipeline of selected compounds in late stage development and a copy of today’s earnings call presentation can be found on the company’s website at www.investor.jnj.com.

NOTE TO INVESTORS CONCERNING FORWARD-LOOKING STATEMENTS

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, future operating and financial performance, product development, market position and business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: economic and financial market factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the company to successfully execute strategic plans, including restructuring plans; the impact of business combinations and divestitures, including the Company’s ability to successfully integrate Actelion Ltd.’s products and operations and realize the expected benefits and opportunities of the transaction in the expected time frame or at all; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; increased scrutiny of the health care industry by government agencies; and the potential failure to meet obligations in compliance agreements with government bodies. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended January 1, 2017, including under "Item 1A. Risk Factors," its most recently filed Quarterly Report on Form 10-Q, including in the section captioned "Cautionary Note Regarding Forward-Looking Statements," and the company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.investor.jnj.com, or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)   SECOND QUARTER                                    SIX MONTHS
                                                      Percent Change                                    Percent Change
                                   2017       2016    Total    Operations  Currency  2017       2016    Total    Operations  Currency
Sales to customers by
segment of business
Consumer
U.S.                               $   1,487  1,384   7.4   %  7.4         -         $   2,901  2,742   5.8   %  5.8         -
International                      1,991      2,035   (2.2)    (1.1)       (1.1)     3,805      3,872   (1.7)    (1.3)       (0.4)
                                   3,478      3,419   1.7      2.3         (0.6)     6,706      6,614   1.4      1.6         (0.2)
Pharmaceutical
U.S.                               5,010      5,144   (2.6)    (2.6)       -         9,882      10,081  (2.0)    (2.0)       -
International                      3,625      3,510   3.3      6.1         (2.8)     6,998      6,751   3.7      5.9         (2.2)
                                   8,635      8,654   (0.2)    1.0         (1.2)     16,880     16,832  0.3      1.2         (0.9)
Medical Devices
U.S.                               3,229      3,044   6.1      6.1         -         6,321      6,070   4.1      4.1         -
International                      3,497      3,365   3.9      5.8         (1.9)     6,698      6,448   3.9      5.3         (1.4)
                                   6,726      6,409   4.9      5.9         (1.0)     13,019     12,518  4.0      4.7         (0.7)
U.S.                               9,726      9,572   1.6      1.6         -         19,104     18,893  1.1      1.1         -
International                      9,113      8,910   2.3      4.4         (2.1)     17,501     17,071  2.5      4.0         (1.5)
Worldwide                          $ 18,839   18,482  1.9   %  2.9         (1.0)     $ 36,605   35,964  1.8   %  2.5         (0.7)
Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)   SECOND QUARTER                                    SIX MONTHS
                                                      Percent Change                                   Percent Change
                                   2017       2016    Total    Operations  Currency  2017      2016    Total    Operations  Currency
Sales to customers by
geographic area
U.S.                               $   9,726  9,572   1.6   %  1.6         -         $ 19,104  18,893  1.1   %  1.1         -
Europe                             4,232      4,090   3.5      6.7         (3.2)     8,090     7,937   1.9      5.4         (3.5)
Western Hemisphere excluding U.S.  1,499      1,542   (2.8)    (2.7)       (0.1)     2,953     2,873   2.8      (0.2)       3.0
Asia-Pacific, Africa               3,382      3,278   3.2      4.9         (1.7)     6,458     6,261   3.1      4.1         (1.0)
International                      9,113      8,910   2.3      4.4         (2.1)     17,501    17,071  2.5      4.0         (1.5)
Worldwide                          $ 18,839   18,482  1.9   %  2.9         (1.0)     $ 36,605  35,964  1.8   %  2.5         (0.7)
Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except Per Share Figures)                 SECOND QUARTER
                                                                  2017                   2016                   Percent
                                                                               Percent                Percent   Increase
                                                                  Amount       to Sales  Amount       to Sales  (Decrease)
Sales to customers                                                $ 18,839     100.0     $ 18,482     100.0     1.9
Cost of products sold                                             5,823        30.9      5,336        28.9      9.1
Selling, marketing and administrative expenses                    5,262        28.0      5,176        28.0      1.7
Research and development expense                                  2,285        12.1      2,264        12.2      0.9
In-process research and development                               -            -         29           0.2
Interest (income) expense, net                                    122          0.6       102          0.6
Other (income) expense, net                                       588          3.1       557          3.0
Restructuring                                                     11           0.1       114          0.6
Earnings before provision for taxes on income                     4,748        25.2      4,904        26.5      (3.2)
Provision for taxes on income                                     921          4.9       907          4.9       1.5
Net earnings                                                      $   3,827    20.3      $   3,997    21.6      (4.3)
Net earnings per share (Diluted)                                  $     1.40             $     1.43             (2.1)
Average shares outstanding (Diluted)                              2,741.5                2,794.2
Effective tax rate                                                19.4       %           18.5       %
Adjusted earnings before provision for taxes and net earnings (1)
Earnings before provision for taxes on income                     $   6,285    33.4      $   6,024    32.6      4.3
Net earnings                                                      $   5,017    26.6      $   4,866    26.3      3.1
Net earnings per share (Diluted)                                  $     1.83             $     1.74             5.2
Effective tax rate                                                20.2       %           19.2       %
(1) See Reconciliation of Non-GAAP Financial Measures.
Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except Per Share Figures)                 SIX MONTHS
                                                                  2017                   2016                   Percent
                                                                               Percent                Percent   Increase
                                                                  Amount       to Sales  Amount       to Sales  (Decrease)
Sales to customers                                                $ 36,605     100.0     $ 35,964     100.0     1.8
Cost of products sold                                             11,209       30.6      10,665       29.6      5.1
Selling, marketing and administrative expenses                    9,999        27.3      9,864        27.4      1.4
Research and development expense                                  4,345        11.9      4,277        11.9      1.6
In-process research and development                               -            -         29           0.1
Interest (income) expense, net                                    205          0.6       179          0.5
Other (income) expense, net                                       428          1.2       518          1.4
Restructuring                                                     96           0.2       234          0.7
Earnings before provision for taxes on income                     10,323       28.2      10,198       28.4      1.2
Provision for taxes on income                                     2,074        5.7       1,744        4.9       18.9
Net earnings                                                      $   8,249    22.5      $   8,454    23.5      (2.4)
Net earnings per share (Diluted)                                  $     3.00             $     3.02             (0.7)
Average shares outstanding (Diluted)                              2,749.4                2,800.9
Effective tax rate                                                20.1       %           17.1       %
Adjusted earnings before provision for taxes and net earnings (1)
Earnings before provision for taxes on income                     $ 12,388     33.8      $ 11,825     32.9      4.8
Net earnings                                                      $ 10,055     27.5      $   9,720    27.0      3.4
Net earnings per share (Diluted)                                  $     3.66             $     3.47             5.5
Effective tax rate                                                18.8       %           17.8       %
(1) See Reconciliation of Non-GAAP Financial Measures.
Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
                                                             Second Quarter                           % Incr. /                           Six Months YTD                            % Incr. /
(Dollars in Millions Except Per Share Data)                  2017                              2016   (Decr.)                             2017                              2016    (Decr.)
Earnings before provision for taxes on income - as reported  $ 4,748                           4,904  (3.2)                            %  $ 10,323                          10,198  1.2                              %
Intangible asset amortization expense                        480                               326                                        809                               608
Litigation expense, net                                      493                               600                                        493                               666
Restructuring/Other (1)                                      128                               141                                        289                               278
Actelion acquisition related cost                            213                               -                                          213                               -
Diabetes asset impairment                                    182                               -                                          182                               -
AMO acquisition related cost                                 41                                -                                          79                                -
In-process research and development                          -                                 29                                         -                                 29
Other                                                        -                                 24                                         -                                 46
Earnings before provision for taxes on income - as adjusted  $ 6,285                           6,024  4.3                              %  $ 12,388                          11,825  4.8                              %
Net Earnings - as reported                                   $ 3,827                           3,997  (4.3)                            %  $   8,249                         8,454   (2.4)                            %
Intangible asset amortization expense                        378                               238                                        622                               443
Litigation expense, net                                      352                               493                                        352                               549
Restructuring/Other                                          101                               97                                         222                               217
Actelion acquisition related cost                            199                               -                                          199                               -
Diabetes asset impairment                                    125                               -                                          125                               -
AMO acquisition related cost                                 35                                -                                          286                               -
In-process research and development                          -                                 23                                         -                                 23
Other                                                        -                                 18                                         -                                 34
Net Earnings - as adjusted                                   $ 5,017                           4,866  3.1                              %  $ 10,055                          9,720   3.4                              %
Diluted Net Earnings per share - as reported                 $   1.40                          1.43   (2.1)                            %  $     3.00                        3.02    (0.7)                            %
Intangible asset amortization expense                        0.14                              0.08                                       0.23                              0.16
Litigation expense, net                                      0.13                              0.18                                       0.13                              0.19
Restructuring/Other                                          0.03                              0.03                                       0.08                              0.08
Actelion acquisition related cost                            0.07                              -                                          0.07                              -
Diabetes asset impairment                                    0.05                              -                                          0.05                              -
AMO acquisition related cost                                 0.01                              -                                          0.10                              -
In-process research and development                          -                                 0.01                                       -                                 0.01
Other                                                        -                                 0.01                                       -                                 0.01
Diluted Net Earnings per share - as adjusted                 $   1.83                          1.74   5.2                              %  $     3.66                        3.47    5.5                              %
Operational Diluted Net Earnings per share - as adjusted
at 2015 foreign currency exchange rates                                                        1.74                                                                         3.51
Impact of currency at 2016 foreign currency exchange rates   0.03                              -                                          0.06                              (0.04)
Operational Diluted Net Earnings per share - as adjusted
at 2016 foreign currency exchange rates                      $   1.86                          1.74   6.9                              %  $     3.72                        3.47    7.2                              %
(1)Includes $13M recorded in cost of products sold and $104M recorded in other (income) expense for the second quarter 2017. Includes $17M recorded in cost of products sold and $176M recorded in other (income) expense for six months 2017 YTD.  Includes $7M recorded in cost of products sold and $20M recorded in other (income) expense for the  second quarter 2016.  Includes $24M recorded in cost of products sold and $20M recorded in other (income) expense for six months 2016 YTD.
Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Operational Sales Growth Excluding Acquisitions and Divestitures
SECOND QUARTER 2017 ACTUAL vs. 2016 ACTUAL
Segments
                                                                     Consumer  Pharmaceutical  Medical Devices  Total
                                                                     Operational %(1)
WW As Reported:                                                      2.3%      1.0%            5.9%             2.9%
U.S.                                                                 7.4%      (2.6)%          6.1%             1.6%
International                                                        (1.1)%    6.1%            5.8%             4.4%
Beauty
Vogue                                                                (2.7)                                      (0.5)
U.S.                                                                 (5.9)                                      (0.9)
International                                                        (0.6)                                      (0.1)
Other Neuroscience
Controlled Substance Raw Material and API Business                             0.6                              0.3
U.S.                                                                           0.8                              0.4
International                                                                  0.5                              0.2
Diagnostics
Ortho-Clinical Diagnostics                                                                     0.5              0.2
U.S.                                                                                           0.0              0.0
International                                                                                  1.0              0.3
Vision Care
Abbott Medical Optics                                                                          (5.1)            (1.8)
U.S.                                                                                           (4.6)            (1.5)
International                                                                                  (5.6)            (2.1)
Pulmonary Hypertension
Actelion                                                                       (1.1)                            (0.5)
U.S.                                                                           (0.8)                            (0.4)
International                                                                  (1.5)                            (0.6)
All Other Acquisitions and Divestitures                              (0.4)                     (0.2)            (0.1)
U.S.                                                                 (0.3)                     (0.7)            (0.2)
International                                                        (0.6)                     0.2              (0.1)
WW Ops excluding Acquisitions and Divestitures                       (0.8)%    0.5%            1.1%             0.5%
U.S.                                                                 1.2%      (2.6)%          0.8%             (1.0)%
International                                                        (2.3)%    5.1%            1.4%             2.0%
(1)Operational growth excludes the effect of translational currency
Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Operational Sales Growth Excluding Acquisitions and Divestitures
SIX MONTHS 2017 ACTUAL vs. 2016 ACTUAL
Segments
                                                                     Consumer  Pharmaceutical  Medical Devices  Total
                                                                     Operational %(1)
WW As Reported:                                                      1.6%      1.2%            4.7%             2.5%
U.S.                                                                 5.8%      (2.0)%          4.1%             1.1%
International                                                        (1.3)%    5.9%            5.3%             4.0%
Beauty
Vogue                                                                (2.9)                                      (0.5)
U.S.                                                                 (6.1)                                      (0.9)
International                                                        (0.7)                                      (0.2)
Other Neuroscience
Controlled Substance Raw Material and API Business                             0.7                              0.3
U.S.                                                                           0.9                              0.5
International                                                                  0.4                              0.2
Diagnostics
Ortho-Clinical Diagnostics                                                                     0.5              0.2
U.S.                                                                                           0.0              0.0
International                                                                                  1.0              0.4
Vision Care
Abbott Medical Optics                                                                          (3.6)            (1.3)
U.S.                                                                                           (3.2)            (1.0)
International                                                                                  (4.0)            (1.5)
Pulmonary Hypertension
Actelion                                                                       (0.6)                            (0.3)
U.S.                                                                           (0.4)                            (0.2)
International                                                                  (0.8)                            (0.3)
All Other Acquisitions and Divestitures                              (0.3)                     (0.2)            (0.1)
U.S.                                                                 (0.5)                     (0.7)            (0.4)
International                                                        (0.1)                     0.2              0.1
WW Ops excluding Acquisitions and Divestitures                       (1.6)%    1.3%            1.4%             0.8%
U.S.                                                                 (0.8)%    (1.5)%          0.2%             (0.9)%
International                                                        (2.1)%    5.5%            2.5%             2.7%
(1)Operational growth excludes the effect of translational currency
                                    REPORTED SALES vs. PRIOR PERIOD ($MM)
                                    SECOND QUARTER                                                             SIX MONTHS
                                                                            % Change                                                                             % Change
                                       2017             2016                Reported Operational (1) Currency     2017                    2016                   Reported Operational (1) Currency
CONSUMER SEGMENT (2) (3)
BABY CARE
US                                     $           113  $               126 -10.3%   -10.3%          -            $                  226  $                  247 -8.5%    -8.5%           -
Intl                                   381              404                 -5.7%    -5.3%           -0.4%        723                     766                    -5.6%    -5.7%           0.1%
WW                                     494              530                 -6.8%    -6.5%           -0.3%        949                     1,013                  -6.3%    -6.3%           0.0%
BEAUTY
US                                     649              554                 17.1%    17.1%           -            1,216                   1,038                  17.1%    17.1%           -
Intl                                   427              422                 1.2%     3.1%            -1.9%        841                     817                    2.9%     4.0%            -1.1%
WW                                     1,076            976                 10.2%    11.0%           -0.8%        2,057                   1,855                  10.9%    11.4%           -0.5%
ORAL CARE
US                                     150              159                 -5.7%    -5.7%           -            306                     329                    -7.0%    -7.0%           -
Intl                                   244              244                 0.0%     0.8%            -0.8%        450                     459                    -2.0%    -1.7%           -0.3%
WW                                     394              403                 -2.2%    -1.7%           -0.5%        756                     788                    -4.1%    -3.9%           -0.2%
OTC
US                                     432              405                 6.7%     6.7%            -            909                     871                    4.4%     4.4%            -
Intl                                   574              591                 -2.9%    -1.1%           -1.8%        1,110                   1,124                  -1.2%    -0.2%           -1.0%
WW                                     1,006            996                 1.0%     2.1%            -1.1%        2,019                   1,995                  1.2%     1.8%            -0.6%
WOMEN’S HEALTH
US                                     3                7                   -57.1%   -57.1%          -            6                       13                     -53.8%   -53.8%          -
Intl                                   273              276                 -1.1%    -1.9%           0.8%         512                     521                    -1.7%    -3.0%           1.3%
WW                                     276              283                 -2.5%    -3.3%           0.8%         518                     534                    -3.0%    -4.2%           1.2%
WOUND CARE / OTHER
US                                     140              133                 5.3%     5.3%            -            238                     244                    -2.5%    -2.5%           -
Intl                                   92               98                  -6.1%    -4.8%           -1.3%        169                     185                    -8.6%    -8.3%           -0.3%
WW                                     232              231                 0.4%     0.9%            -0.5%        407                     429                    -5.1%    -5.0%           -0.1%
TOTAL CONSUMER
US                                     1,487            1,384               7.4%     7.4%            -            2,901                   2,742                  5.8%     5.8%            -
Intl                                   1,991            2,035               -2.2%    -1.1%           -1.1%        3,805                   3,872                  -1.7%    -1.3%           -0.4%
WW                                     $        3,478   $            3,419  1.7%     2.3%            -0.6%        $               6,706   $               6,614  1.4%     1.6%            -0.2%
                                    REPORTED SALES vs. PRIOR PERIOD ($MM)
                                    SECOND QUARTER                                                             SIX MONTHS
                                                                            % Change                                                                             % Change
                                       2017             2016                Reported Operational (1) Currency     2017                    2016                   Reported Operational (1) Currency
PHARMACEUTICAL SEGMENT (2) (3)
IMMUNOLOGY
US                                     $        2,101   $            2,224  -5.5%    -5.5%           -            $               4,224   $               4,395  -3.9%    -3.9%           -
Intl                                   858              814                 5.4%     8.0%            -2.6%        1,665                   1,553                  7.2%     8.5%            -1.3%
WW                                     2,959            3,038               -2.6%    -1.9%           -0.7%        5,889                   5,948                  -1.0%    -0.7%           -0.3%
REMICADE
US                                     1,064            1,236               -13.9%   -13.9%          -            2,246                   2,447                  -8.2%    -8.2%           -
US Exports (4)                         127              185                 -31.4%   -31.4%          -            292                     418                    -30.1%   -30.1%          -
Intl                                   339              359                 -5.6%    -3.4%           -2.2%        664                     694                    -4.3%    -4.0%           -0.3%
WW                                     1,530            1,780               -14.0%   -13.6%          -0.4%        3,202                   3,559                  -10.0%   -9.9%           -0.1%
SIMPONI / SIMPONI ARIA
US                                     230              244                 -5.7%    -5.7%           -            459                     460                    -0.2%    -0.2%           -
Intl                                   209              204                 2.5%     4.6%            -2.1%        408                     378                    7.9%     8.6%            -0.7%
WW                                     439              448                 -2.0%    -1.0%           -1.0%        867                     838                    3.5%     3.8%            -0.3%
STELARA
US                                     680              559                 21.6%    21.6%           -            1,227                   1,070                  14.7%    14.7%           -
Intl                                   303              245                 23.7%    27.5%           -3.8%        579                     469                    23.5%    26.8%           -3.3%
WW                                     983              804                 22.3%    23.4%           -1.1%        1,806                   1,539                  17.3%    18.3%           -1.0%
OTHER IMMUNOLOGY
US                                     -                -                   -        -               -            -                       -                      -        -               -
Intl                                   7                6                   16.7%    15.8%           0.9%         14                      12                     16.7%    14.0%           2.7%
WW                                     7                6                   16.7%    15.8%           0.9%         14                      12                     16.7%    14.0%           2.7%
INFECTIOUS DISEASES
US                                     341              362                 -5.8%    -5.8%           -            667                     720                    -7.4%    -7.4%           -
Intl                                   451              467                 -3.4%    -1.5%           -1.9%        874                     885                    -1.2%    0.6%            -1.8%
WW                                     792              829                 -4.5%    -3.4%           -1.1%        1,541                   1,605                  -4.0%    -3.0%           -1.0%
EDURANT
US                                     17               14                  21.4%    21.4%           -            29                      25                     16.0%    16.0%           -
Intl                                   162              126                 28.6%    30.9%           -2.3%        299                     234                    27.8%    30.6%           -2.8%
WW                                     179              140                 27.9%    30.0%           -2.1%        328                     259                    26.6%    29.2%           -2.6%
PREZISTA / PREZCOBIX / REZOLSTA
US                                     278              273                 1.8%     1.8%            -            537                     550                    -2.4%    -2.4%           -
Intl                                   176              186                 -5.4%    -2.9%           -2.5%        347                     361                    -3.9%    -1.4%           -2.5%
WW                                     454              459                 -1.1%    -0.1%           -1.0%        884                     911                    -3.0%    -2.0%           -1.0%
OTHER INFECTIOUS DISEASES
US                                     46               75                  -38.7%   -38.7%          -            101                     145                    -30.3%   -30.3%          -
Intl                                   113              155                 -27.1%   -26.3%          -0.8%        228                     290                    -21.4%   -21.5%          0.1%
WW                                     159              230                 -30.9%   -30.4%          -0.5%        329                     435                    -24.4%   -24.4%          0.0%
See footnotes at end of schedule
                                    REPORTED SALES vs. PRIOR PERIOD ($MM)
                                    SECOND QUARTER                                                             SIX MONTHS
                                                                            % Change                                                                             % Change
                                       2017             2016                Reported Operational (1) Currency     2017                    2016                   Reported Operational (1) Currency
NEUROSCIENCE
US                                     620              695                 -10.8%   -10.8%          -            1,284                   1,375                  -6.6%    -6.6%           -
Intl                                   847              907                 -6.6%    -4.1%           -2.5%        1,680                   1,776                  -5.4%    -3.5%           -1.9%
WW                                     1,467            1,602               -8.4%    -7.0%           -1.4%        2,964                   3,151                  -5.9%    -4.9%           -1.0%
CONCERTA / METHYLPHENIDATE
US                                     76               129                 -41.1%   -41.1%          -            184                     263                    -30.0%   -30.0%          -
Intl                                   105              109                 -3.7%    -1.3%           -2.4%        206                     206                    0.0%     1.3%            -1.3%
WW                                     181              238                 -23.9%   -22.8%          -1.1%        390                     469                    -16.8%   -16.2%          -0.6%
INVEGA SUSTENNA / XEPLION / TRINZA
US                                     387              339                 14.2%    14.2%           -            759                     644                    17.9%    17.9%           -
Intl                                   242              221                 9.5%     13.1%           -3.6%        474                     429                    10.5%    13.7%           -3.2%
WW                                     629              560                 12.3%    13.7%           -1.4%        1,233                   1,073                  14.9%    16.2%           -1.3%
RISPERDAL CONSTA
US                                     91               100                 -9.0%    -9.0%           -            186                     195                    -4.6%    -4.6%           -
Intl                                   116              130                 -10.8%   -8.1%           -2.7%        228                     266                    -14.3%   -12.0%          -2.3%
WW                                     207              230                 -10.0%   -8.5%           -1.5%        414                     461                    -10.2%   -8.9%           -1.3%
OTHER NEUROSCIENCE
US                                     66               127                 -48.0%   -48.0%          -            155                     273                    -43.2%   -43.2%          -
Intl                                   384              447                 -14.1%   -12.1%          -2.0%        772                     875                    -11.8%   -10.6%          -1.2%
WW                                     450              574                 -21.6%   -20.0%          -1.6%        927                     1,148                  -19.3%   -18.4%          -0.9%
ONCOLOGY
US                                     697              569                 22.5%    22.5%           -            1,361                   1,118                  21.7%    21.7%           -
Intl                                   1,030            905                 13.8%    17.0%           -3.2%        1,960                   1,710                  14.6%    17.6%           -3.0%
WW                                     1,727            1,474               17.2%    19.2%           -2.0%        3,321                   2,828                  17.4%    19.2%           -1.8%
DARZALEX
US                                     212              95                  *        *               -            413                     196                    *        *               -
Intl                                   87               13                  *        *               **           141                     13                     *        *               **
WW                                     299              108                 *        *               **           554                     209                    *        *               **
IMBRUVICA
US                                     202              144                 40.3%    40.3%           -            392                     276                    42.0%    42.0%           -
Intl                                   248              151                 64.2%    69.4%           -5.2%        467                     280                    66.8%    71.4%           -4.6%
WW                                     450              295                 52.5%    55.1%           -2.6%        859                     556                    54.5%    56.8%           -2.3%
VELCADE
US                                     -                -                   -        -               -            -                       -                      -        -               -
Intl                                   290              342                 -15.2%   -12.6%          -2.6%        570                     646                    -11.8%   -9.0%           -2.8%
WW                                     290              342                 -15.2%   -12.6%          -2.6%        570                     646                    -11.8%   -9.0%           -2.8%
ZYTIGA
US                                     241              286                 -15.7%   -15.7%          -            474                     558                    -15.1%   -15.1%          -
Intl                                   317              315                 0.6%     3.2%            -2.6%        607                     601                    1.0%     3.0%            -2.0%
WW                                     558              601                 -7.2%    -5.8%           -1.4%        1,081                   1,159                  -6.7%    -5.7%           -1.0%
OTHER ONCOLOGY
US                                     42               44                  -4.5%    -4.5%           -            82                      88                     -6.8%    -6.8%           -
Intl                                   88               84                  4.8%     7.1%            -2.3%        175                     170                    2.9%     5.5%            -2.6%
WW                                     130              128                 1.6%     3.1%            -1.5%        257                     258                    -0.4%    1.3%            -1.7%
PULMONARY HYPERTENSION (5)
US                                     40               -                   **       **              -            40                      -                      **       **              -
Intl                                   51               -                   **       **              -            51                      -                      **       **              -
WW                                     91               -                   **       **              -            91                      -                      **       **              -
OPSUMIT                                                 -
US                                     24               -                   **       **              -            24                      -                      **       **              -
Intl                                   21               -                   **       **              -            21                      -                      **       **              -
WW                                     45               -                   **       **              -            45                      -                      **       **              -
TRACLEER                                                -
US                                     2                -                   **       **              -            2                       -                      **       **              -
Intl                                   24               -                   **       **              -            24                      -                      **       **              -
WW                                     26               -                   **       **              -            26                      -                      **       **              -
UPTRAVI                                                 -
US                                     8                -                   **       **              -            8                       -                      **       **              -
Intl                                   1                -                   **       **              -            1                       -                      **       **              -
WW                                     9                -                   **       **              -            9                       -                      **       **              -
OTHER(6)                                                -
US                                     6                -                   **       **              -            6                       -                      **       **              -
Intl                                   5                -                   **       **              -            5                       -                      **       **              -
WW                                     11               -                   **       **              -            11                      -                      **       **              -
CARDIOVASCULAR / METABOLISM / OTHER
US                                     1,211            1,294               -6.4%    -6.4%           -            2,306                   2,473                  -6.8%    -6.8%           -
Intl                                                 388               417                 -7.0%           -3.0%           -4.0%        768                     827                    -7.1%    -3.7%           -3.4%
WW                                                   1,599             1,711               -6.5%           -5.5%           -1.0%        3,074                   3,300                  -6.8%    -6.0%           -0.8%
XARELTO
US                                                   642               594                 8.1%            8.1%            -            1,155                   1,161                  -0.5%    -0.5%           -
Intl                                                 -                 -                   -               -               -            -                       -                      -        -               -
WW                                                   642               594                 8.1%            8.1%            -            1,155                   1,161                  -0.5%    -0.5%           -
INVOKANA / INVOKAMET
US                                                   256               348                 -26.4%          -26.4%          -            503                     645                    -22.0%   -22.0%          -
Intl                                                 39                35                  11.4%           16.8%           -5.4%        76                      63                     20.6%    23.9%           -3.3%
WW                                                   295               383                 -23.0%          -22.5%          -0.5%        579                     708                    -18.2%   -17.9%          -0.3%
PROCRIT / EPREX
US                                                   174               230                 -24.3%          -24.3%          -            343                     413                    -16.9%   -16.9%          -
Intl                                                 81                92                  -12.0%          -9.7%           -2.3%        159                     183                    -13.1%   -11.3%          -1.8%
WW                                                   255               322                 -20.8%          -20.1%          -0.7%        502                     596                    -15.8%   -15.3%          -0.5%
OTHER
US                                                   139               122                 13.9%           13.9%           -            305                     254                    20.1%    20.1%           -
Intl                                                 268               290                 -7.6%           -3.3%           -4.3%        533                     581                    -8.3%    -4.4%           -3.9%
WW                                                   407               412                 -1.2%           1.9%            -3.1%        838                     835                    0.4%     3.1%            -2.7%
TOTAL PHARMACEUTICAL
US                                                   5,010             5,144               -2.6%           -2.6%           -            9,882                   10,081                 -2.0%    -2.0%           -
Intl                                                 3,625             3,510               3.3%            6.1%            -2.8%        6,998                   6,751                  3.7%     5.9%            -2.2%
WW                                                   $        8,635    8,654               -0.2%           1.0%            -1.2%        $             16,880    16,832                 0.3%     1.2%            -0.9%
See footnotes at end of schedule
                                    REPORTED SALES vs. PRIOR PERIOD ($MM)
                                    SECOND QUARTER                                                                                   SIX MONTHS
                                                                                           % Change                                                                                    % Change
MEDICAL DEVICES SEGMENT (2)                          2017              2016                Reported        Operational (1) Currency     2017                    2016                   Reported Operational (1) Currency
CARDIOVASCULAR
US                                                   $           265   235                 12.8%           12.8%           -            $                  524  466                    12.4%    12.4%           -
Intl                                                 258               235                 9.8%            12.3%           -2.5%        498                     447                    11.4%    13.2%           -1.8%
WW                                                   523               470                 11.3%           12.6%           -1.3%        1,022                   913                    11.9%    12.8%           -0.9%
DIABETES CARE
US                                                   160               177                 -9.6%           -9.6%           -            314                     357                    -12.0%   -12.0%          -
Intl                                                 261               294                 -11.2%          -9.5%           -1.7%        506                     543                    -6.8%    -5.5%           -1.3%
WW                                                   421               471                 -10.6%          -9.5%           -1.1%        820                     900                    -8.9%    -8.1%           -0.8%
DIAGNOSTICS
US                                                   -                 -                   -               -               -            -                       -                      -        -               -
Intl                                                 -                 31                  **              **              **           1                       59                     **       **              **
WW                                                   -                 31                  **              **              **           1                       59                     **       **              **
ORTHOPAEDICS
US                                                   1,387             1,364               1.7%            1.7%            -            2,766                   2,756                  0.4%     0.4%            -
Intl                                                 956               991                 -3.5%           -1.4%           -2.1%        1,902                   1,940                  -2.0%    -0.3%           -1.7%
WW                                                   2,343             2,355               -0.5%           0.4%            -0.9%        4,668                   4,696                  -0.6%    0.1%            -0.7%
HIPS
US                                                   208               197                 5.6%            5.6%            -            417                     400                    4.3%     4.3%            -
Intl                                                 142               152                 -6.6%           -4.3%           -2.3%        285                     291                    -2.1%    -0.1%           -2.0%
WW                                                   350               349                 0.3%            1.3%            -1.0%        702                     691                    1.6%     2.4%            -0.8%
KNEES
US                                                   236               229                 3.1%            3.1%            -            482                     473                    1.9%     1.9%            -
Intl                                                 149               156                 -4.5%           -2.5%           -2.0%        301                     301                    0.0%     2.1%            -2.1%
WW                                                   385               385                 0.0%            0.8%            -0.8%        783                     774                    1.2%     2.0%            -0.8%
TRAUMA
US                                                   390               381                 2.4%            2.4%            -            781                     762                    2.5%     2.5%            -
Intl                                                 253               255                 -0.8%           1.1%            -1.9%        504                     516                    -2.3%    -1.0%           -1.3%
WW                                                   643               636                 1.1%            1.9%            -0.8%        1,285                   1,278                  0.5%     1.0%            -0.5%
SPINE & OTHER
US                                                   553               557                 -0.7%           -0.7%           -            1,086                   1,121                  -3.1%    -3.1%           -
Intl                                                 412               428                 -3.7%           -1.6%           -2.1%        812                     832                    -2.4%    -0.7%           -1.7%
WW                                                   965               985                 -2.0%           -1.1%           -0.9%        1,898                   1,953                  -2.8%    -2.1%           -0.7%
SURGERY
US                                                   1,012             1,020               -0.8%           -0.8%           -            2,007                   2,001                  0.3%     0.3%            -
Intl                                                 1,372             1,377               -0.4%           1.6%            -2.0%        2,648                   2,624                  0.9%     2.4%            -1.5%
WW                                                   2,384             2,397               -0.5%           0.6%            -1.1%        4,655                   4,625                  0.6%     1.5%            -0.9%
ADVANCED
US                                                   400               389                 2.8%            2.8%            -            792                     741                    6.9%     6.9%            -
Intl                                                 533               520                 2.5%            4.9%            -2.4%        1,018                   984                    3.5%     5.4%            -1.9%
WW                                                   933               909                 2.6%            4.0%            -1.4%        1,810                   1,725                  4.9%     6.0%            -1.1%
GENERAL
US                                                   423               421                 0.5%            0.5%            -            846                     840                    0.7%     0.7%            -
Intl                                                 691               706                 -2.1%           -0.2%           -1.9%        1,342                   1,357                  -1.1%    0.4%            -1.5%
WW                                                   1,114             1,127               -1.2%           0.0%            -1.2%        2,188                   2,197                  -0.4%    0.5%            -0.9%
SPECIALTY
US                                                   189               210                 -10.0%          -10.0%          -            369                     420                    -12.1%   -12.1%          -
Intl                                                 148               151                 -2.0%           -1.0%           -1.0%        288                     283                    1.8%     1.7%            0.1%
WW                                                   337               361                 -6.6%           -6.2%           -0.4%        657                     703                    -6.5%    -6.5%           0.0%
VISION CARE
US                                                   405               248                 63.3%           63.3%           -            710                     490                    44.9%    44.9%           -
Intl                                                 650               437                 48.7%           50.3%           -1.6%        1,143                   835                    36.9%    37.6%           -0.7%
WW                                                   1,055             685                 54.0%           55.0%           -1.0%        1,853                   1,325                  39.8%    40.2%           -0.4%
CONTACT LENSES / OTHER
US                                                   274               248                 10.5%           10.5%           -            530                     490                    8.2%     8.2%            -
Intl                                                 479               437                 9.6%            11.2%           -1.6%        906                     835                    8.5%     9.2%            -0.7%
WW                                                   753               685                 9.9%            10.9%           -1.0%        1,436                   1,325                  8.4%     8.8%            -0.4%
SURGICAL
US                                                   131               -                   **              **              -            180                     -                      **       **              -
Intl                                                 171               -                   **              **              -            237                     -                      **       **              -
WW                                                   302               -                   **              **              -            417                     -                      **       **              -
TOTAL MEDICAL DEVICES
US                                                   3,229             3,044               6.1%            6.1%            -            6,321                   6,070                  4.1%     4.1%            -
Intl                                                 3,497             3,365               3.9%            5.8%            -1.9%        6,698                   6,448                  3.9%     5.3%            -1.4%
WW                                                   $        6,726    6,409               4.9%            5.9%            -1.0%        $             13,019    12,518                 4.0%     4.7%            -0.7%
* Percentage greater than 100%
** Not meaningful
(1) Operational growth excludes the effect of translational currency
(2) Unaudited
(3) Prior year amounts have been reclassified to conform to current year product disclosure
(4) Reported as U.S. sales
(5) Actelion acquisition completed June 16, 2017
(6) Includes Non-Pulmonary Hypertension products

View original content with multimedia:http://www.prnewswire.com/news-releases/johnson--johnson-reports-2017-second-quarter-results-3004897

SOURCE Johnson & Johnson

https://rt.prnewswire.com/rt.gif?NewsItemId=NY44174&Transmission_Id=201707180640PR_NEWS_USPR_____NY44174&DateId=20170718



Register |  Password |  Feedback |  Copyright |  Usage Agreement |  Privacy Policy |  Advertising |  About Us |  Contact Us |  FAQ 

Past performance is not indicative of future results

StockSelector.com, the StockSelector.com logo, and News Selects are trademarks of StockSelector.com.
Copyright © 1998 - 2017 StockSelector.com. All rights reserved.